Role of IL-17 and IL-22 in autoimmunity and cancer.
The dysregulation of inflammatory cytokines can cause a variety of diseases, such as autoimmunity and cancer. Since their identification in 2005, Th17 cells and its signature cytokine IL-17, have been implicated in the pathogenesis of autoimmune diseases such as psoriasis and rheumatoid arthritis (RA), and inflammatory associated cancers such as colorectal carcinoma (CRC). Recently, IL-22 a Th17 related cytokine has been shown to be pathogenic in psoriasis and RA. In this review, we will summarize the biological functions of IL-17 and IL-22, their role in autoimmune diseases and briefly review results from clinical trials targeting IL-17 or its receptor for the treatment of autoimmune diseases. Next, we will discuss pre-clinical and clinical data supporting the rationale of targeting other cytokines implicated in the Th17/IL-17 pathway, such as IL-22 and IL-23. Finally, we discuss the role of IL-17, and in particularly IL-22 in tumour immunity and possible therapeutic interventions.
Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Queensland, Australia.
S J
SJ
Blake
Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Queensland, Australia; School of Medicine, University of Queensland, Queensland, Australia. Electronic address: michele.teng@qimrberghofer.edu.au.
M W L
MW
Teng
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D057134:Antibodies, Neutralizing / Q000276:immunology / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000276:immunology / Q000473:pathology; D015551:Autoimmunity / Q000276:immunology*; D002986:Clinical Trials as Topic; D004847:Epithelial Cells / Q000473:pathology; D006801:Humans; D018928:Immunity, Mucosal / Q000276:immunology; D007167:Immunotherapy; D007249:Inflammation / Q000276:immunology; D020381:Interleukin-17 / Q000037:antagonists & inhibitors / Q000276:immunology / Q000502:physiology*; D007378:Interleukins / Q000276:immunology / Q000502:physiology*; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy; D018123:Receptors, Interleukin / Q000276:immunology / Q000502:physiology; D053722:Receptors, Interleukin-17 / Q000037:antagonists & inhibitors; D058504:Th17 Cells / Q000276:immunology; D000097043:Interleukin-22
D000911:Antibodies, Monoclonal; D057134:Antibodies, Neutralizing; D020381:Interleukin-17; D007378:Interleukins; D018123:Receptors, Interleukin; D053722:Receptors, Interleukin-17; D000097043:Interleukin-22; C415369:interleukin-22 receptor
Autoimmunity; Autoinmunidad; Cancer; Cáncer; IL-22